These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 28850565

  • 1. Dovitinib in patients with gastrointestinal stromal tumour refractory and/or intolerant to imatinib.
    Joensuu H, Blay JY, Comandone A, Martin-Broto J, Fumagalli E, Grignani G, Del Muro XG, Adenis A, Valverde C, Pousa AL, Bouché O, Italiano A, Bauer S, Barone C, Weiss C, Crippa S, Camozzi M, Castellana R, Le Cesne A.
    Br J Cancer; 2017 Oct 24; 117(9):1278-1285. PubMed ID: 28850565
    [Abstract] [Full Text] [Related]

  • 2. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'.
    Schöffski P, Mir O, Kasper B, Papai Z, Blay JY, Italiano A, Benson C, Kopeckova K, Ali N, Dileo P, LeCesne A, Menge F, Cousin S, Wardelmann E, Wozniak A, Marreaud S, Litiere S, Zaffaroni F, Nzokirantevye A, Vanden Bempt I, Gelderblom H.
    Eur J Cancer; 2020 Jul 24; 134():62-74. PubMed ID: 32470848
    [Abstract] [Full Text] [Related]

  • 3. Phase II study of dovitinib in patients with metastatic and/or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Kang YK, Yoo C, Ryoo BY, Lee JJ, Tan E, Park I, Park JH, Choi YJ, Jo J, Ryu JS, Ryu MH.
    Br J Cancer; 2013 Oct 29; 109(9):2309-15. PubMed ID: 24084771
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of TAS-116, an oral inhibitor of heat shock protein 90, in patients with metastatic or unresectable gastrointestinal stromal tumour refractory to imatinib, sunitinib and regorafenib: a phase II, single-arm trial.
    Doi T, Kurokawa Y, Sawaki A, Komatsu Y, Ozaka M, Takahashi T, Naito Y, Ohkubo S, Nishida T.
    Eur J Cancer; 2019 Nov 29; 121():29-39. PubMed ID: 31536852
    [Abstract] [Full Text] [Related]

  • 5. Phase II Trial of Continuous Regorafenib Dosing in Patients with Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib.
    Kim JJ, Ryu MH, Yoo C, Beck MY, Ma JE, Kang YK.
    Oncologist; 2019 Nov 29; 24(11):e1212-e1218. PubMed ID: 31036770
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
    Raut CP, Espat NJ, Maki RG, Araujo DM, Trent J, Williams TF, Purkayastha DD, DeMatteo RP.
    JAMA Oncol; 2018 Dec 01; 4(12):e184060. PubMed ID: 30383140
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. RACK1 overexpression is linked to acquired imatinib resistance in gastrointestinal stromal tumor.
    Gao X, Xue A, Fang Y, Shu P, Ling J, Hou Y, Shen K, Qin J, Sun Y, Qin X.
    Oncotarget; 2016 Mar 22; 7(12):14300-9. PubMed ID: 26893362
    [Abstract] [Full Text] [Related]

  • 10. A Phase I Study of Binimetinib (MEK162) Combined with Pexidartinib (PLX3397) in Patients with Advanced Gastrointestinal Stromal Tumor.
    Rosenbaum E, Kelly C, D'Angelo SP, Dickson MA, Gounder M, Keohan ML, Movva S, Condy M, Adamson T, Mcfadyen CR, Antonescu CR, Hwang S, Singer S, Qin LX, Tap WD, Chi P.
    Oncologist; 2019 Oct 22; 24(10):1309-e983. PubMed ID: 31213500
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
    Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.
    Eur J Cancer; 2010 May 22; 46(8):1344-51. PubMed ID: 20211560
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
    George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD.
    Eur J Cancer; 2009 Jul 22; 45(11):1959-68. PubMed ID: 19282169
    [Abstract] [Full Text] [Related]

  • 15. Inhibition effect of Peg-IFNα-2b and Imatinib alone or combination on imatinib-resistant gastrointestinal stromal tumors cell lines.
    Zhang LY, Huang JS, Pi ZM, Yu MY.
    Int J Clin Exp Pathol; 2015 Jul 22; 8(9):11340-7. PubMed ID: 26617858
    [Abstract] [Full Text] [Related]

  • 16. Imatinib escalation or sunitinib treatment after first-line imatinib in metastatic gastrointestinal stromal tumor patients.
    Hsu CC, Wu CE, Chen JS, Tseng JH, Chiang KC, Liu YY, Tsai CY, Cheng CT, Chen TW, Jan YY, Yeh TS, Chen YY, Yeh CN.
    Anticancer Res; 2014 Sep 22; 34(9):5029-36. PubMed ID: 25202087
    [Abstract] [Full Text] [Related]

  • 17. Long-term follow-up outcome of imatinib mesylate treatment for recurrent and unresectable gastrointestinal stromal tumors.
    Saito S, Nakata K, Kajiura S, Ando T, Hosokawa A, Sugiyama T.
    Digestion; 2013 Sep 22; 87(1):47-52. PubMed ID: 23343969
    [Abstract] [Full Text] [Related]

  • 18. Clinical and Biomarker Analysis of a Phase I/II Study of PDR001 Plus Imatinib for Advanced Treatment-Refractory Gastrointestinal Stromal Tumors.
    Kim HD, Ryu MH, Park YS, Yoo C, Kim SJ, Kang YK.
    Clin Cancer Res; 2024 Jul 01; 30(13):2743-2750. PubMed ID: 38662455
    [Abstract] [Full Text] [Related]

  • 19. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
    Casali PG, Le Cesne A, Poveda Velasco A, Kotasek D, Rutkowski P, Hohenberger P, Fumagalli E, Judson IR, Italiano A, Gelderblom H, Adenis A, Hartmann JT, Duffaud F, Goldstein D, Broto JM, Gronchi A, Dei Tos AP, Marréaud S, van der Graaf WT, Zalcberg JR, Litière S, Blay JY.
    J Clin Oncol; 2015 Dec 20; 33(36):4276-83. PubMed ID: 26573069
    [Abstract] [Full Text] [Related]

  • 20. Managing progressive disease in patients with GIST: factors to consider besides acquired secondary tyrosine kinase inhibitor resistance.
    Patel S.
    Cancer Treat Rev; 2012 Aug 20; 38(5):467-72. PubMed ID: 22035971
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.